Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4CNS 4Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Breast 3Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Myeloproliferative Syndrome, Transient 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cytarabine 9Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Methotrexate 5fludarabine 4nilotinib 3merphos 3fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Polymerase Chain Reaction 3Mitoxantrone 3Melphalan 3Idarubicin 3Daunorubicin 3Cytogenetic Analysis 3Cyclosporine 3Asparaginase 3bosutinib 2Thioguanine 2Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Observation × Myeloid × Clear all
NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Children's Oncology Group

Phase 3 Withdrawn
MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡